This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children

This study has been completed.
Information provided by:
Montefiore Medical Center Identifier:
First received: September 13, 2007
Last updated: October 26, 2009
Last verified: October 2009
The objective of this study is to compare the efficacy of the Synera patch applied for 20 minutes with the efficacy of EMLA Cream applied for 60 minutes in reducing pain associated with venipunctures in children.

Condition Intervention
Pain Drug: EMLA Cream Drug: Synera Patch

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children

Further study details as provided by Montefiore Medical Center:

Primary Outcome Measures:
  • Child rating of Pain [ Time Frame: after venipuncture ]

Secondary Outcome Measures:
  • Parent rating of child's pain [ Time Frame: after venipuncture ]
  • Blinded observer ratings of child's pain [ Time Frame: before, during, and after venipuncture ]

Estimated Enrollment: 100
Study Start Date: September 2007
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A, 1
EMLA Cream will be applied to venipuncture site
Drug: EMLA Cream
60 minutes x1
Active Comparator: A, 2
The Synera Patch will be applied to the venipuncture site
Drug: Synera Patch
20 minutes x1


Ages Eligible for Study:   4 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children in outpatient clinics requiring venipuncture for medical care
  • Ages 4-12 years old
  • The ability to demonstrate proper understanding of the Wong-Baker FACES Pain Ranking Scale
  • Parents of enrolled children need to be present during the procedure and be willing to rate their child's pain

Exclusion Criteria:

  • Damaged or inflamed skin at the designated application site
  • Known sensitivity to components of Synera or EMLA (lidocaine, tetracaine, or local anesthetics of the amide or sdter type, PABA derivatives)
  • Contraindications to SYnera or EMLA use (Severe hepatic disease, history of drug-induced methemoglobinemia, taking Class 1 antiarrhythmics)
  • Use of analgesics during the past 24 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00530803

United States, New York
Children's Hospital at Montefiore
Bronx, New York, United States, 10467
Sponsors and Collaborators
Montefiore Medical Center
Principal Investigator: Catherine C Skae, MD Children's Hospital at Montefiore
  More Information

Publications: Identifier: NCT00530803     History of Changes
Other Study ID Numbers: MontefioreMC
Study First Received: September 13, 2007
Last Updated: October 26, 2009

Keywords provided by Montefiore Medical Center:

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anesthetics, Combined
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017